High and prolonged sulfamidase secretion by the liver of MPS-IIIA mice following hydrodynamic tail vein delivery of antibiotic-free pFAR4 plasmid vector

Gene Therapy

Volumn 21, Issue 12, 2014, Pages 1001-1007

  Quiviger, M ^a,b,c   Arfi, A ^a,b,c   Mansard, D ^a,b,c   Delacotte, L ^a,b,c   Pastor, M ^a,b,c   Scherman, D ^a,b,c   Marie, C ^a,b,c  

^a Centre National de la Recherche Scientifique   (France)

^b PSL RESEARCH UNIVERSITY   (France)

^c CNRS   (France)

Author keywords

[No Author keywords available]

Indexed keywords

HYDROLASE; KANAMYCIN; PFAR4 VECTOR; PLASMID VECTOR; SULFAMIDASE; UNCLASSIFIED DRUG; VIRUS VECTOR; GLYCOSAMINOGLYCAN; N-SULFOGLUCOSAMINE SULFOHYDROLASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BIOSAFETY; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME RELEASE; EXPRESSION VECTOR; GENE; GENE THERAPY; GENE VECTOR; HYDRODYNAMICS BASED TRANSFECTION; LIVER; MOUSE; N SULFOGLUCOSAMINE SULFOHYDROLASE GENE; NONHUMAN; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; REPORTER GENE; SANFILIPPO SYNDROME; ANIMAL; COPY NUMBER VARIATION; DISEASE MODEL; ENZYMOLOGY; GENE TRANSFER; GENETICS; METABOLISM; MUCOPOLYSACCHARIDOSIS III; PLASMID; PROCEDURES; SECRETION (PROCESS);

MUS;

ANIMALS; DISEASE MODELS, ANIMAL; DNA COPY NUMBER VARIATIONS; GENE TRANSFER TECHNIQUES; GENETIC THERAPY; GENETIC VECTORS; GLYCOSAMINOGLYCANS; HYDROLASES; LIVER; MICE; MUCOPOLYSACCHARIDOSIS III; PLASMIDS;

EID: 84927136705     PISSN: 09697128     EISSN: 14765462     Source Type: Journal    
DOI: 10.1038/gt.2014.75     Document Type: Article

References (46)

1. Ginn SL, Alexander IE, Edelstein ML, Abedi MR, Wixon J. Gene therapy clinical trials worldwide to 2012 - an update. J Gene Med 2013; 15: 65-77
2. Rols MP. Mechanism by which electroporation mediates DNA migration and entry into cells and targeted tissues. Methods Mol Biol 2008; 423: 19-33
3. Delalande A, Kotopoulis SMP, Midoux P, Pichon C. Sonoporation: mechanistic insights and ongoing challenges for gene transfer. Gene 2013; 525: 191-199
4. Escoffre JM, Zeghimi A, Novell A, Bouakaz A. In-vivo gene delivery by sonoporation: recent progress and prospects. Curr Gene Ther 2013; 13: 2-14
5. Sawyer GJ, Rela M, Davenport M, Whitehorne M, Zhang X, Fabre JW. Hydrodynamic gene delivery to the liver: theoretical and practical issues for clinical application. Curr Gene Ther 2009; 9: 128-135
6. Kamimura K, Suda T, Kanefuji T, Zhang G, Aoyagi Y, Liu D. Image-guided, lobe-specific hydrodynamic gene delivery to baboon liver. Mol Ther 2012; 20: S37 (Abstract 89
7. Yokoo T, Kamimura K, Suda T, Kanefuji T, Oda M, Zhang G., et al. Novel electric power-driven hydrodynamic injection system for gene delivery: safety and efficacy of human factor IX delivery in rats. Gene Therapy 2013; 20: 816-823
8. Marie C, Vandermeulen G, Quiviger M, Richard M, Préat V, Scherman D. pFARs, Plasmids free of antibiotic resistance markers, display high-level transgene expression in muscle, skin and tumour cells. J Gene Med 2010; 12: 323-332
9. Kreiss P, Cameron B, Rangara R, Mailhe P, Aguerre-Charriol O, Airiau M., et al. Plasmid DNA size does not affect the physiochemical properties of lipoplexes but modulates gene transfer efficiency. Nucleic Acids Res 1999; 27: 3792-3798
10. Bloquel C, Fabre E, Bureau MF, Scherman D. Plasmid DNA electrotransfer for intracellular and secreted proteins expression: new methodological developments and applications. J Gene Med 2004; 6: S11-S13
11. Valstar MJ, Ruijter GJG, Van Diggelen OP, Poorthuis BJ, Wijburg FA. Sanfilippo syndrome: a mini-review. J Inherit Metab Dis 2008; 31: 240-252
12. Oussoren E, Brands MMMG, Ruijter GJG, Van Der Ploeg AT, Reuser AJJ. Bone, joint and tooth development in mucopolysaccharidoses: relevance to therapeutic options. Biochim Biophys Acta 2011; 1812: 1542-1556
13. Valstar MJ, Neijs S, Bruggenwirth HT, Olmer R, Ruijter GJG, Wevers RA., et al. Mucopolysaccharidosis Type IIIA: clinical spectrum and genotype-phenotype correlations. Ann Neurol 2010; 68: 876-887
14. Ruzo A, Marco S, Garcia M, Villacampa P, Ribera A, Ayuso E., et al. Correction of pathological accumulation of glycosaminoglycans in central nervous system and peripheral tissues of MPSIIIA mice through systemic AAV9 gene transfer. Hum Gene Ther 2012; 23: 1237-1246
15. Ruzo A, Garcia M, Ribera A, Villacampa P, Haurigot V, Marco S., et al. Liver production of sulfamidase reverses peripheral and ameliorates CNS pathology in mucopolysaccharidosis IIIA mice. Mol Ther 2012; 20: 254-266
16. Sorrentino NC, D'Orsi A, Sambri I, Nusco E, Monaco C, Spampanato C., et al. A highly secreted sulphamidase engineered to cross the blood-brain barrier corrects brain lesions of mice with mucopolysaccharidoses type IIIA. EMBO Mol Med 2013; 5: 675-690
17. McIntyre C, Byers S, Anson DS. Correction of mucopolysaccharidosis type IIIA somatic and central nervous system pathology by lentiviral-mediated gene transfer. J Gene Med 2010; 12: 717-728
18. Langford-Smith A, Wilkinson FL, Langford-Smith KJ, Holley RJ, Sergijenko A, Howe SJ., et al. Hematopietic stem cell and gene therapy corrects primary neuropathology and behavior in mucopolysaccharidosis IIIA mice. Mol Ther 2012; 20: 1610-1621
19. Savas PS, Hemsley KM, Hopwood JJ. Intracerebral injection of sulfamidase delays neuropathology in murine MPS-IIIA. Mol Genet Metab 2004; 82: 273-285
20. Hemsley KM, Norman EJ, Crawley AC, Auclair D, King B, Fuller M., et al. Effect of cisternal sulfamidase delivery in MPS IIIA Huntaway dogs - a proof of principle study. Mol Genet Metab 2009; 98: 383-392
21. Delgadillo V, del Mar O'Callaghan M, Artuch R, Montero R, Pineda M. Genistein supplementation in patients affected by Sanfilippo disease. J Inherit Metab Dis 2011; 34: 1039-1045
22. Piotrowska E, Jakobkiewicz-Banecka J, Maryniak A, Tylki-Szymanska A, Puk E, Liberek A., et al. Two-year follow-up of Sanfilippo disease patients treated with a genistein-rich isoflavone extract: assessment of effects on cognitive functions and general status of patients. Med Sci Monit 2011; 17: 196-202
23. de Ruijter J, Valstar MJ, Narajczyk M, Wegrzyn G, Kulik W, Ijlst L., et al. Genistein in Sanfilippo disease: a randomized controlled crossover trial. Ann Neurol 2012; 71: 110-120
24. Tardieu M, Zérah M, Husson B, de Bournonville S, Deiva K, Adamsbaum C., et al. Intracerebral administration of AAVrh.10 carrying human SGSH and SUMF1 cDNAs in children with MPSIIIA disease: results of a phase I/II trial. Hum Gene Ther 2014; 25: 506-516
25. Bhaumik M, Muller VJ, Rozaklis T, Johnson L, Dobrenis K, Bhattacharyya B., et al. A mouse model for mucopolysaccharidosis type III A (Sanfilippo syndrome). Glycobiology 1999; 9: 1389-1396
26. Neufeld EF, Fratantoni J-C. Inborn errors of mucopolysaccharide metabolism. Faulty degradative mechanisms are implicated in this group of human diseases. Science 1970; 169: 141-146
27. Liu F, Song Y, Liu D. Hydrodynamics-based transfection in animals by systemic administration of plasmid DNA. Gene Therapy 1999; 6: 1258-1266
28. Kobayashi N, Nishikawa M, Hirata K, Takakura Y. Hydrodynamics-based procedure involves transient hyperpermeability in the hepatic cellular membrane: implication of a nonspecific process in efficient intracellular gene delivery. J Gene Med 2004; 6: 584-592
29. Héron B, Mikaeloff Y, Froissart R, Caridade G, Maire I, Caillaud C., et al. Incidence and natural history of mucopolysaccharidosis type III in France and comparison with United Kingdom and Greece. Am J Med Genet 2010; 155A: 58-68
30. Vogler C, Levy B, Grubb JH, Galvin N, Tan Y, Kakkis E., et al. Overcoming the blood-brain barrier with high-dose enzyme replacement therapy in murine mucopolysaccharidosis VII. Proc Natl Acad Sci USA 2005; 102: 14777-14782
31. Osborn MJ, McElmurry RT, Lees CJ, DeFeo AP, Chen Z-Y, Kay MA., et al. Minicircle DNA-based gene therapy coupled with immune modulation permits long-term expression of a-L-Iduronidase in mice with mucopolysaccharidosis type I. Mol Ther 2011; 19: 450-460
32. Ohmi K, Greenberg DS, Rajavel KS, Ryazantsev S, Li HH, Neufeld EF. Activated microglia in cortex of mouse models of mucopolysaccharidoses I and IIIB. Proc Natl Acad Sci USA 2003; 100: 1902-1907
33. Arfi A, Richard M, Gandolphe C, Bonnefont-Rousselot D, Thérond P, Scherman D. Neuroinflammatory and oxidative stress phenomena in MPS IIIA mouse model: the positive effect of long-term aspirin treatment. Mol Genet Metab 2011; 103: 18-25
34. Riu E, Chen Z-Y, Xu H, He C-Y, Kay MA. Histone modifications are associated with the persistence or silencing of vector-mediated transgene expression in vivo. Mol Ther 2007; 15: 1348-1355
35. Gracey Maniar LE, Maniar JM, Chen ZY, Lu J, Fire AZ, Kay MA. Minicircle DNA vectors achieve sustained expression reflected by active chromatin and transcriptional level. Mol Ther 2013; 21: 131-138
36. Lu J, Zhang F, Xu S, Fire AZ, Kay MA. The extragenic spacer length between the 5' and 3' ends of the transgene expression cassette affects transgene silencing from plasmid-based vectors. Mol Ther 2012; 20: 2111-2119
37. Vogler C, Levy B, Galvin NJ, Thorpe C, Sands MS, Barker JE., et al. Enzyme replacement in murine mucopolysaccharidosis type VII: neuronal and glial response to ß-glucuronidase requires early initiation of enzyme replacement therapy. Pediatr Res 1999; 45: 838-844
38. Urayama A, Grubb JH, Sly WS, Banks WA. Developmentally regulated mannose 6-phosphate receptor-mediated transport of a lysosomal enzyme across the blood-brain barrier. Proc Natl Acad Sci USA 2004; 101: 12658-12663
39. Urayama A, Grubb JH, Sly WS, Banks WA. Mannose 6-p hosphate receptor-mediated transport of sulfamidase across the blood-brain barrier in the newborn mouse. Proc Natl Acad Sci USA 2008; 16: 1261-1266
40. Wang D, Zhang W, Kalfa TA, Grabowski G, Davies S, Malik P., et al. Reprogramming erythroid cells for lysosomal enzyme production leads to visceral and CNS crosscorrection in mice with Hurler syndrome. Proc Natl Acad Sci USA 2009; 106: 19958-19963
41. Rozaklis T, Beard H, Hassiotis S, Garcia AR, Tonini M, Luck A., et al. Impact of highdose, chemically modified sulfamidase on pathology in a murine model of MPS IIIA. Exp Neurol 2011; 230: 123-130
42. Bhattacharyya B, Gliddon B, Beccari T, Hopwood JJ, Stanley P. A novel missense mutation in lysosomal sulfamidase in the basis of MPS III A in a spontaneous mouse mutant. Glycobiology 2001; 11: 99-103
43. Zhang G, Budker V, Wolff JA. High levels of foreign gene expression in hepatocytes after tail vein injections of naked plasmid DNA. Hum Gene Ther 1999; 10: 1735-1737
44. Karpova EA, Voznyi YV, Keulemans JLM, Hoogeveen AT, Winchester B, Tsvetkova IV., et al. A fluorimetric enzyme assay for the diagnosis of Sanfilippo disease type A (MPS IIIA). J Inherit Metab Dis 1996; 19: 278-285
45. Bloquel C, Trollet C, Pradines E, Seguin J, Scherman D, Bureau MF. Optical imaging of luminescence for in vivo quantification of gene electrotransfer in mouse muscle and knee. BMC Biotechnol 2006; 6: 16
46. Richard M, Arfi A, Seguin J, Gandolphe C, Scherman D. Widespread biochemical correction of murine mucopolysaccharidosis type VII pathology by liver hydrodynamic plasmid delivery. Gene Therapy 2009; 16: 746-756